Company profile
Scilex Holding Co
NASDAQ:SCLXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Celecoxib | approved | — | 6 | approved |
| Colchicine | approved | — | 4 | approved |
| Lidocaine | approved | — | 1 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (0)
No records yet.
FDA applications (3)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 207962 | NDA | SCILEX PHARMACEUTICALS INC | ||||
Loading… | ||||||
| NDA 210942 | NDA | SCILEX PHARMACEUTICALS INC | ||||
Loading… | ||||||
| NDA 212157 | NDA | SCILEX PHARMACEUTICALS INC | ||||
Loading… | ||||||